Ow S

ORCID: 0000-0002-2229-7971 · 1 paper in corpus · active 2020
2020
A multicenter phase II randomized trial of durvalumab (MEDI-4736) versus physician's choice chemotherapy in recurrent ovarian clear cell adenocarcinoma (MOCCA).
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society ·doi:10.1136/ijgc-2020-001604

BackgroundThe optimal treatment of recurrent ovarian clear cell carcinoma remains unknown. There is increasing rationale to support the role of immune checkpoint inhibitors targeting the programmed cell death protein 1 (PD-1)/programmed dea…